DEN-181, a subcutaneous formulation consisting of RA-joint HLA-DRB1*04:01- and *01:01-haplotypes specific collagen type II259-273 peptide and NF-κB pathway inhibitor calcitriol in liposome formulation, reduced the population of citrullinated vimentin-specific T cells in MTX-treated patients under a phase I clinical trial (204). This evidence concerns the gene VIM and rheumatoid arthritis.